Deals
SpaceX Bought Cursor for $60B Days After IPO
SpaceX's $60B Cursor deal prices the startup at 23x revenue. Days after the IPO. The catch: Anthropic already controls half the AI coding market.
Deals — Page 2
M&A, fundraising, IPOs, and bankruptcies in regulated industries.
Deals
DOJ Cleared $111B Paramount Deal; Staff Wanted to Sue
DOJ greenlit a $111B streaming merger over the objections of its own antitrust staff, and state AGs are already lining up a lawsuit to stop it.
Deals
Salesforce Buys Fin for $3.6B at 9x ARR
Salesforce's $3.6B buy of Fin prices its Apex model at nine times ARR, an 80% premium to the company's last reported secondary valuation.
Deals
Fox Bought Roku for $22B at $160 a Share
Fox agreed to pay $160 a share for Roku, a $22B bet that owning the streaming distribution pipe is worth more than just filling it with content.
Deals
Mistral Seeks $3.5B at $23B Valuation
Mistral's new round would price the French startup at €20B, a 71% jump over last September's Series C, as it pitches European banks on sovereign AI.
Deals
Lilly Paid $2.3B for Ajax: Phase 1 Data Show Why
Lilly's $2.3B Ajax bet just got its first clinical proof: AJ1-11095 hit 70% SVR35, more than double the historical ceiling for pre-treated MF.
Deals
Biopharma Shed 6,956 Jobs in May, Takeda Leads
Biopharma cut nearly 7,000 jobs in May, a 47% YoY surge: Takeda's 4,500 restructuring targets 200B yen in savings, BioNTech another €500M.
Deals
Amazon Files $17.5B Credit Facility for AI
Amazon's $17.5B delayed-draw loan carries a Sept. 30 draw deadline and zero financial covenants, built to fund a $200B AI capex push.
Deals
Lilly Bought 10, Spent $25B: More Than Pharma Combined
Lilly's $25.27B deal spree in 2026 eclipses the combined M&A of every other top-12 pharma, and the obesity juggernaut isn't done yet.
Deals
J&J Buys Firefly Bio for $1B DAC Platform
J&J dropped $1 billion on a preclinical KRAS degrader platform at the exact moment Revolution Medicines proved the target is druggable.
Deals
Intesa Outbids BPM for Monte Paschi at $35.3B
Intesa Sanpaolo bid $35.3 billion for Monte Paschi at a 12.5% premium, blocking a BPM merger-of-equals offer that never named a price.
Deals
Roche Pays $700M Upfront for Nurix BTK Degrader
Roche drops $700M upfront and up to $3B total for Nurix's bexobrutideg, a BTK degrader headed into a phase 3 showdown with Lilly's Jaypirca.
Deals
S&P Blocks SpaceX, Freezes $14B Passive Flow
S&P held its profitability screen, costing SpaceX $14B in passive fund demand and putting OpenAI and Anthropic on the same minimum one-year clock.
Deals
Google Rents SpaceX Compute at $920M Monthly
Google rents 110,000 Nvidia GPUs from SpaceX at $920M a month, bridging a Gemini Enterprise demand surge that a $190B capex plan can't keep pace with.
Deals
Exited: Revolut CTO, Two CFOs in One Week
Nubank hired a former Visa North America CFO, Revolut downgraded its CTO title, and Adyen's CFO quit for a job outside fintech, all in one week.
Deals
Alphabet Prices $84.75B Record AI Equity Sale
Alphabet priced an $84.75B equity sale on June 2, the largest stock offering in recorded history, with Berkshire Hathaway in for $10B.
Deals
Alphabet Raises $80B; Berkshire Buys $10B Stake
Alphabet's $80B equity raise, anchored by Berkshire's $10B, signals the moment AI capex outpaces Big Tech's collective ability to self-fund.
Deals
Paid £15B in Year One, Amazon Ahead on £40B UK Pledge
Amazon hit £15 billion of a £40 billion UK pledge in year one, ahead of pace, while embedding a new payment into Prime's billing chain.
Deals
Lilly Paid $1.26B to License Hanmi's GLP-2
Lilly's $75M upfront bet on Hanmi's once-monthly GLP-2 could reach $1.26B if sonefpeglutide survives FDA, and its main rival already stumbled.
Deals
Lilly Paid $3.2B for Kelonia's 100% CAR-T Response
Lilly's $3.2B upfront bet on Kelonia just got its first real validation: 18 of 18 myeloma patients hit MRD-negative status at one month.
